The stiff competition between Moderna, Inc. and Pfizer Inc./BioNTech SE on COVID-19 vaccines will likely continue as Moderna has produced positive results for its bivalent vaccine designed to protect against the original strain of the virus as well as variants of concern, while Pfizer/BioNTech develop their own monovalent, Omicron-specific vaccine candidate.
On 19 April, Moderna announced data from one cohort of its Phase II/III study that tested mRNA-1273.211, a bivalent COVID-19 vaccine, given as a 50mcg booster shot to adults who had previously received two shots of the original vaccine, mRNA-1273, which now has US Food and Drug Administration approval under the brand name Spikevax, as part of the Phase III COVE trial
